Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
December 17, 2020 08:30 ET
|
Ehave
MIAMI, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, announces...
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets
December 16, 2020 08:30 ET
|
Ehave
MIAMI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
December 14, 2020 08:07 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
June 15, 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...
Ehave, Inc. PsyTech Welcomes Todd Shapiro of Red Light Holland as Moderator in the June 17th Webinar The Future of Psychedelics: A TECHNOLOGY PERSPECTIVE
June 11, 2020 09:00 ET
|
Ehave
MIAMI, June 11, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), and its subsidiary PsyTech, announced an upcoming Psychedelic Industry Webinar. The complimentary virtual...
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
May 19, 2020 09:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
May 18, 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 10:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 12, 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
April 08, 2020 09:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...